Fmr LLC Has $6.78 Million Holdings in Genmab A/S (NASDAQ:GMAB)

Fmr LLC raised its holdings in Genmab A/S (NASDAQ:GMAB) by 13.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 278,194 shares of the company’s stock after acquiring an additional 33,076 shares during the period. Fmr LLC’s holdings in Genmab A/S were worth $6,782,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Oppenheimer Asset Management Inc. boosted its holdings in Genmab A/S by 26.3% during the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after purchasing an additional 45,376 shares during the last quarter. Choreo LLC bought a new stake in Genmab A/S during the 2nd quarter worth about $776,000. Renaissance Technologies LLC boosted its stake in shares of Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after buying an additional 103,859 shares during the last quarter. Natixis Advisors LLC grew its holdings in shares of Genmab A/S by 29.8% in the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after acquiring an additional 47,437 shares in the last quarter. Finally, US Bancorp DE increased its position in shares of Genmab A/S by 16.0% in the third quarter. US Bancorp DE now owns 171,669 shares of the company’s stock valued at $4,185,000 after acquiring an additional 23,723 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Price Performance

NASDAQ GMAB opened at $20.65 on Friday. Genmab A/S has a one year low of $20.34 and a one year high of $32.88. The business’s fifty day moving average is $22.27 and its 200-day moving average is $25.17. The stock has a market capitalization of $13.67 billion, a price-to-earnings ratio of 20.05, a PEG ratio of 0.68 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The company had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same period in the previous year, the firm earned $0.47 EPS. Research analysts expect that Genmab A/S will post 1.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on GMAB shares. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Truist Financial reduced their price target on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a report on Monday, September 9th. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Redburn Atlantic started coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, Morgan Stanley reissued an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.